Communicators

are winners!

More News

27.09.2022
Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs
01.09.2022
Recce Pharmaceuticals Appoints Alistair McKeough to Board of Directors
22.08.2022
Positive Safety Data from Seventh Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
11.07.2022
Recce Pharmaceuticals: Appointment of Dr Philip Sutton as Vice President of Translational Sciences
21.06.2022
Positive Safety Data from Sixth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
20.05.2022
Recce Pharmaceuticals Ltd.: Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE® 327 and Initiates Sixth Cohort at 4,000mg
12.04.2022
Phase I Clinical Trial of RECCE® 327 Advances to High Dose Level (2,000mg I.V)
11.04.2022
Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
30.03.2022
Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
28.03.2022
RECCE: R&D Incentive Rebate Received